Cargando…

Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report

While standard treatment has shown efficacy in patients with breast cancer gene (BRCA) mutations, recurrence rates are high and additional effective therapies are needed. Olaparib, a poly adenosine diphosphate–ribose polymerase (PARP) inhibitor, approved for the treatment of metastatic germline BRCA...

Descripción completa

Detalles Bibliográficos
Autores principales: Caputo, Roberta, Pagliuca, Martina, Pensabene, Matilde, Parola, Sara, De Laurentiis, Michelino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438988/
https://www.ncbi.nlm.nih.gov/pubmed/37601649
http://dx.doi.org/10.3389/fonc.2023.1214660
_version_ 1785092840691335168
author Caputo, Roberta
Pagliuca, Martina
Pensabene, Matilde
Parola, Sara
De Laurentiis, Michelino
author_facet Caputo, Roberta
Pagliuca, Martina
Pensabene, Matilde
Parola, Sara
De Laurentiis, Michelino
author_sort Caputo, Roberta
collection PubMed
description While standard treatment has shown efficacy in patients with breast cancer gene (BRCA) mutations, recurrence rates are high and additional effective therapies are needed. Olaparib, a poly adenosine diphosphate–ribose polymerase (PARP) inhibitor, approved for the treatment of metastatic germline BRCA1/BRCA2 breast cancer (BC), has demonstrated evidence of a progression-free survival (PFS) benefit, good safety profile, and improved quality of life compared with standard chemotherapy. We here describe the case of a patient with BRCA1 mutated advanced BC and a long history of response to chemotherapy and immunotherapy who received systemic treatment with olaparib. First diagnosed in March 2011 at the age of 38 years with early-stage BC of the right breast, she underwent quadrantectomy plus ipsilateral axillary lymphadenectomy and adjuvant treatments with chemotherapy regimen containing 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) followed by radiotherapy. Five years later, following a contralateral nodule detection leading to left breast quadrantectomy, she received adjuvant systemic treatment with docetaxel plus cyclophosphamide and radiotherapy. Gene testing showed a germline BRCA1 deleterious variant, and she underwent bilateral prophylactic mastectomy and oophorectomy. One year later, skin metastasis and bone infiltrations were detected, and she was started on first-line systemic treatment. The patient was enrolled in the IMpassion131 trial (investigating atezolizumab addition to paclitaxel) but unblinding showed that she was randomized in the placebo arm. She received second-line systemic therapy with LAG525 plus carboplatin (CLAG525B2101 trial) resulting in a PFS of 14 months. At disease progression, she was eligible for systemic third-line therapy with olaparib (300 mg twice daily) and had a complete response after 6 months of therapy and a PFS of 40 months at the time of writing. To the best of our knowledge, this is the first report of a complete response following treatment with third-line systemic olaparib in a long-responding patient and relatively good tolerability and quality of life, pre-treated with both chemotherapy and immunotherapy.
format Online
Article
Text
id pubmed-10438988
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104389882023-08-19 Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report Caputo, Roberta Pagliuca, Martina Pensabene, Matilde Parola, Sara De Laurentiis, Michelino Front Oncol Oncology While standard treatment has shown efficacy in patients with breast cancer gene (BRCA) mutations, recurrence rates are high and additional effective therapies are needed. Olaparib, a poly adenosine diphosphate–ribose polymerase (PARP) inhibitor, approved for the treatment of metastatic germline BRCA1/BRCA2 breast cancer (BC), has demonstrated evidence of a progression-free survival (PFS) benefit, good safety profile, and improved quality of life compared with standard chemotherapy. We here describe the case of a patient with BRCA1 mutated advanced BC and a long history of response to chemotherapy and immunotherapy who received systemic treatment with olaparib. First diagnosed in March 2011 at the age of 38 years with early-stage BC of the right breast, she underwent quadrantectomy plus ipsilateral axillary lymphadenectomy and adjuvant treatments with chemotherapy regimen containing 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) followed by radiotherapy. Five years later, following a contralateral nodule detection leading to left breast quadrantectomy, she received adjuvant systemic treatment with docetaxel plus cyclophosphamide and radiotherapy. Gene testing showed a germline BRCA1 deleterious variant, and she underwent bilateral prophylactic mastectomy and oophorectomy. One year later, skin metastasis and bone infiltrations were detected, and she was started on first-line systemic treatment. The patient was enrolled in the IMpassion131 trial (investigating atezolizumab addition to paclitaxel) but unblinding showed that she was randomized in the placebo arm. She received second-line systemic therapy with LAG525 plus carboplatin (CLAG525B2101 trial) resulting in a PFS of 14 months. At disease progression, she was eligible for systemic third-line therapy with olaparib (300 mg twice daily) and had a complete response after 6 months of therapy and a PFS of 40 months at the time of writing. To the best of our knowledge, this is the first report of a complete response following treatment with third-line systemic olaparib in a long-responding patient and relatively good tolerability and quality of life, pre-treated with both chemotherapy and immunotherapy. Frontiers Media S.A. 2023-08-04 /pmc/articles/PMC10438988/ /pubmed/37601649 http://dx.doi.org/10.3389/fonc.2023.1214660 Text en Copyright © 2023 Caputo, Pagliuca, Pensabene, Parola and De Laurentiis https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Caputo, Roberta
Pagliuca, Martina
Pensabene, Matilde
Parola, Sara
De Laurentiis, Michelino
Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report
title Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report
title_full Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report
title_fullStr Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report
title_full_unstemmed Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report
title_short Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report
title_sort long-term complete response with third-line parp inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438988/
https://www.ncbi.nlm.nih.gov/pubmed/37601649
http://dx.doi.org/10.3389/fonc.2023.1214660
work_keys_str_mv AT caputoroberta longtermcompleteresponsewiththirdlineparpinhibitorafterimmunotherapyinapatientwithtriplenegativebreastcanceracasereport
AT pagliucamartina longtermcompleteresponsewiththirdlineparpinhibitorafterimmunotherapyinapatientwithtriplenegativebreastcanceracasereport
AT pensabenematilde longtermcompleteresponsewiththirdlineparpinhibitorafterimmunotherapyinapatientwithtriplenegativebreastcanceracasereport
AT parolasara longtermcompleteresponsewiththirdlineparpinhibitorafterimmunotherapyinapatientwithtriplenegativebreastcanceracasereport
AT delaurentiismichelino longtermcompleteresponsewiththirdlineparpinhibitorafterimmunotherapyinapatientwithtriplenegativebreastcanceracasereport